Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 116

1.

Combined targeting of HER-2 and HER-3 represents a promising therapeutic strategy in colorectal cancer.

Conradi LC, Spitzner M, Metzger AL, Kisly M, Middel P, Bohnenberger H, Gaedcke J, Ghadimi MB, Liersch T, Rüschoff J, Beißbarth T, König A, Grade M.

BMC Cancer. 2019 Sep 5;19(1):880. doi: 10.1186/s12885-019-6051-0.

2.

Leukocytosis and neutrophilia as independent prognostic immunological biomarkers for clinical outcome in the CAO/ARO/AIO-04 randomized phase 3 rectal cancer trial.

Diefenhardt M, Hofheinz RD, Martin D, Beißbarth T, Arnold D, Hartmann A, von der Grün J, Grützmann R, Liersch T, Ströbel P, Grabenbauer GG, Rieger M, Fietkau R, Graeven U, Weitz J, Folprecht G, Ghadimi M, Rödel F, Rödel C, Fokas E; German Rectal Cancer Study Group.

Int J Cancer. 2019 Oct 15;145(8):2282-2291. doi: 10.1002/ijc.32274. Epub 2019 Apr 2.

PMID:
30868576
3.

Can clinicopathological parameters predict for lymph node metastases in ypT0-2 rectal carcinoma? Results of the CAO/ARO/AIO-94 and CAO/ARO/AIO-04 phase 3 trials.

von den Grün JM, Hartmann A, Fietkau R, Ghadimi M, Liersch T, Hohenberger W, Weitz J, Sauer R, Wittekind C, Ströbel P, Rödel C, Fokas E; German Rectal Cancer Study Group.

Radiother Oncol. 2018 Sep;128(3):557-563. doi: 10.1016/j.radonc.2018.06.008. Epub 2018 Jun 18.

PMID:
29929861
4.

Association of Plane of Total Mesorectal Excision With Prognosis of Rectal Cancer: Secondary Analysis of the CAO/ARO/AIO-04 Phase 3 Randomized Clinical Trial.

Kitz J, Fokas E, Beissbarth T, Ströbel P, Wittekind C, Hartmann A, Rüschoff J, Papadopoulos T, Rösler E, Ortloff-Kittredge P, Kania U, Schlitt H, Link KH, Bechstein W, Raab HR, Staib L, Germer CT, Liersch T, Sauer R, Rödel C, Ghadimi M, Hohenberger W; German Rectal Cancer Study Group.

JAMA Surg. 2018 Aug 1;153(8):e181607. doi: 10.1001/jamasurg.2018.1607. Epub 2018 Aug 15.

5.

Impact of age on the efficacy of oxaliplatin in the preoperative chemoradiotherapy and adjuvant chemotherapy of rectal cancer: a post hoc analysis of the CAO/ARO/AIO-04 phase III trial.

Hofheinz RD, Arnold D, Fokas E, Kaufmann M, Hothorn T, Folprecht G, Fietkau R, Hohenberger W, Ghadimi M, Liersch T, Grabenbauer GG, Sauer R, Rödel C, Graeven U; German Rectal Cancer Study Group.

Ann Oncol. 2018 Aug 1;29(8):1793-1799. doi: 10.1093/annonc/mdy205.

PMID:
29873684
6.

Long-term prognostic impact of surgical complications in the German Rectal Cancer Trial CAO/ARO/AIO-94.

Sprenger T, Beißbarth T, Sauer R, Tschmelitsch J, Fietkau R, Liersch T, Hohenberger W, Staib L, Gaedcke J, Raab HR, Rödel C, Ghadimi M.

Br J Surg. 2018 Oct;105(11):1510-1518. doi: 10.1002/bjs.10877. Epub 2018 May 30.

PMID:
29846017
7.

Neoadjuvant rectal score as individual-level surrogate for disease-free survival in rectal cancer in the CAO/ARO/AIO-04 randomized phase III trial.

Fokas E, Fietkau R, Hartmann A, Hohenberger W, Grützmann R, Ghadimi M, Liersch T, Ströbel P, Grabenbauer GG, Graeven U, Hofheinz RD, Köhne CH, Wittekind C, Sauer R, Kaufmann M, Hothorn T, Rödel C; German Rectal Cancer Study Group.

Ann Oncol. 2018 Jul 1;29(7):1521-1527. doi: 10.1093/annonc/mdy143.

PMID:
29718095
8.

Tumor Regression Grading After Preoperative Chemoradiotherapy as a Prognostic Factor and Individual-Level Surrogate for Disease-Free Survival in Rectal Cancer.

Fokas E, Ströbel P, Fietkau R, Ghadimi M, Liersch T, Grabenbauer GG, Hartmann A, Kaufmann M, Sauer R, Graeven U, Hoffmanns H, Raab HR, Hothorn T, Wittekind C, Rödel C; German Rectal Cancer Study Group.

J Natl Cancer Inst. 2017 Dec 1;109(12). doi: 10.1093/jnci/djx095.

PMID:
29206996
9.

CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial.

Sinn M, Bahra M, Liersch T, Gellert K, Messmann H, Bechstein W, Waldschmidt D, Jacobasch L, Wilhelm M, Rau BM, Grützmann R, Weinmann A, Maschmeyer G, Pelzer U, Stieler JM, Striefler JK, Ghadimi M, Bischoff S, Dörken B, Oettle H, Riess H.

J Clin Oncol. 2017 Oct 10;35(29):3330-3337. doi: 10.1200/JCO.2017.72.6463. Epub 2017 Aug 17.

PMID:
28817370
10.

The Prognostic Value of Tyrosine Kinase SRC Expression in Locally Advanced Rectal Cancer.

Rühlmann F, Nietert M, Sprenger T, Wolff HA, Homayounfar K, Middel P, Bohnenberger H, Beissbarth T, Ghadimi BM, Liersch T, Conradi LC.

J Cancer. 2017 Apr 10;8(7):1229-1237. doi: 10.7150/jca.16980. eCollection 2017.

11.

Repeated adjuvant anti-CEA radioimmunotherapy after resection of colorectal liver metastases: Safety, feasibility, and long-term efficacy results of a prospective phase 2 study.

Sahlmann CO, Homayounfar K, Niessner M, Dyczkowski J, Conradi LC, Braulke F, Meller B, Beißbarth T, Ghadimi BM, Meller J, Goldenberg DM, Liersch T.

Cancer. 2017 Feb 15;123(4):638-649. doi: 10.1002/cncr.30390. Epub 2016 Oct 20.

12.

Neoadjuvant Therapy in Rectal Cancer - Biobanking of Preoperative Tumor Biopsies.

Jo P, Nietert M, Gusky L, Kitz J, Conradi LC, Müller-Dornieden A, Schüler P, Wolff HA, Rüschoff J, Ströbel P, Grade M, Liersch T, Beißbarth T, Ghadimi MB, Sax U, Gaedcke J.

Sci Rep. 2016 Oct 18;6:35589. doi: 10.1038/srep35589.

13.

[Lymph node metastases in ypT1/2 rectal cancer after neoadjuvant chemoradiotherapy : The Achilles heel of organ-preserving operative procedures?].

Sprenger T, Rothe H, Beissbarth T, Conradi LC, Kauffels A, Homayounfar K, Behnes CL, Rödel C, Liersch T, Ghadimi M.

Chirurg. 2016 Jul;87(7):593-601. doi: 10.1007/s00104-016-0170-9. German.

PMID:
27106241
14.

Stage-Dependent Frequency of Lymph Node Metastases in Patients With Rectal Carcinoma After Preoperative Chemoradiation: Results from the CAO/ARO/AIO-94 Trial and From a Comparative Prospective Evaluation With Extensive Pathological Workup.

Sprenger T, Rothe H, Conradi LC, Beissbarth T, Kauffels A, Kitz J, Homayounfar K, Wolff H, Ströbel P, Ghadimi M, Wittekind C, Sauer R, Rödel C, Liersch T.

Dis Colon Rectum. 2016 May;59(5):377-85. doi: 10.1097/DCR.0000000000000570.

PMID:
27050599
15.

β-catenin-independent WNT signaling and Ki67 in contrast to the estrogen receptor status are prognostic and associated with poor prognosis in breast cancer liver metastases.

Bleckmann A, Conradi LC, Menck K, Schmick NA, Schubert A, Rietkötter E, Arackal J, Middel P, Schambony A, Liersch T, Homayounfar K, Beißbarth T, Klemm F, Binder C, Pukrop T.

Clin Exp Metastasis. 2016 Apr;33(4):309-23. doi: 10.1007/s10585-016-9780-3. Epub 2016 Feb 9.

16.

Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.

Rödel C, Graeven U, Fietkau R, Hohenberger W, Hothorn T, Arnold D, Hofheinz RD, Ghadimi M, Wolff HA, Lang-Welzenbach M, Raab HR, Wittekind C, Ströbel P, Staib L, Wilhelm M, Grabenbauer GG, Hoffmanns H, Lindemann F, Schlenska-Lange A, Folprecht G, Sauer R, Liersch T; German Rectal Cancer Study Group.

Lancet Oncol. 2015 Aug;16(8):979-89. doi: 10.1016/S1470-2045(15)00159-X. Epub 2015 Jul 15.

PMID:
26189067
17.

EGFR and β1-integrin targeting differentially affect colorectal carcinoma cell radiosensitivity and invasion.

Poschau M, Dickreuter E, Singh-Müller J, Zscheppang K, Eke I, Liersch T, Cordes N.

Radiother Oncol. 2015 Sep;116(3):510-6. doi: 10.1016/j.radonc.2015.06.005. Epub 2015 Jun 18.

PMID:
26096850
18.

HER-2 and HER-3 expression in liver metastases of patients with colorectal cancer.

Styczen H, Nagelmeier I, Beissbarth T, Nietert M, Homayounfar K, Sprenger T, Boczek U, Stanek K, Kitz J, Wolff HA, Ghadimi BM, Middel P, Liersch T, Rüschoff J, Conradi LC.

Oncotarget. 2015 Jun 20;6(17):15065-76.

19.

Comprehensive lymph node morphometry in rectal cancer using acetone compression.

Scheel AH, Reineke RA, Sprenger T, Lokka S, Kitz J, Ghadimi BM, Rüschoff J, Liersch T, Middel P.

J Clin Pathol. 2015 Jun;68(6):458-64. doi: 10.1136/jclinpath-2014-202555. Epub 2015 Mar 16.

PMID:
25779094
20.

Downstage migration after neoadjuvant chemoradiotherapy for rectal cancer: the reverse of the Will Rogers phenomenon?

Fokas E, Liersch T, Fietkau R, Hohenberger W, Hess C, Becker H, Sauer R, Wittekind C, Rödel C.

Cancer. 2015 Jun 1;121(11):1724-7. doi: 10.1002/cncr.29260. Epub 2015 Jan 21.

21.

STED super-resolution microscopy of clinical paraffin-embedded human rectal cancer tissue.

Ilgen P, Stoldt S, Conradi LC, Wurm CA, Rüschoff J, Ghadimi BM, Liersch T, Jakobs S.

PLoS One. 2014 Jul 15;9(7):e101563. doi: 10.1371/journal.pone.0101563. eCollection 2014.

22.

Discrepancies between medical oncologists and surgeons in assessment of resectability and indication for chemotherapy in patients with colorectal liver metastases.

Homayounfar K, Bleckmann A, Helms HJ, Lordick F, Rüschoff J, Conradi LC, Sprenger T, Ghadimi M, Liersch T.

Br J Surg. 2014 Apr;101(5):550-7. doi: 10.1002/bjs.9436. Epub 2014 Feb 20.

PMID:
24756914
23.

Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: updated results of the CAO/ARO/AIO-94 trial.

Fokas E, Liersch T, Fietkau R, Hohenberger W, Beissbarth T, Hess C, Becker H, Ghadimi M, Mrak K, Merkel S, Raab HR, Sauer R, Wittekind C, Rödel C.

J Clin Oncol. 2014 May 20;32(15):1554-62. doi: 10.1200/JCO.2013.54.3769. Epub 2014 Apr 21.

PMID:
24752056
24.

Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study).

Folprecht G, Gruenberger T, Bechstein W, Raab HR, Weitz J, Lordick F, Hartmann JT, Stoehlmacher-Williams J, Lang H, Trarbach T, Liersch T, Ockert D, Jaeger D, Steger U, Suedhoff T, Rentsch A, Köhne CH.

Ann Oncol. 2014 May;25(5):1018-25. doi: 10.1093/annonc/mdu088. Epub 2014 Feb 27.

PMID:
24585720
25.

Oxaliplatin-Induced Leukocytoclastic Vasculitis under Adjuvant Chemotherapy for Colorectal Cancer: Two Cases of a Rare Adverse Event.

Quack H, Erpenbeck L, Wolff HA, Sprenger T, Seitz CS, Schön MP, Neumann S, Stanek K, Ghadimi BM, Michels B, Middel P, Schaefer IM, Liersch T, Conradi LC.

Case Rep Oncol. 2013 Dec 11;6(3):609-15. doi: 10.1159/000357166. eCollection 2013 Sep.

26.

Preoperative chemoradiation therapy with capecitabine/oxaliplatin and cetuximab in rectal cancer: long-term results of a prospective phase 1/2 study.

Fokas E, Conradi L, Weiss C, Sprenger T, Middel P, Rau T, Dellas K, Kitz J, Rödel F, Sauer R, Rüschoff J, Beissbarth T, Arnold D, Ghadimi BM, Rödel C, Liersch T.

Int J Radiat Oncol Biol Phys. 2013 Dec 1;87(5):992-9. doi: 10.1016/j.ijrobp.2013.09.011. Epub 2013 Oct 24.

PMID:
24210078
27.

Lymph node metastases in rectal cancer after preoperative radiochemotherapy: impact of intramesorectal distribution and residual micrometastatic involvement.

Sprenger T, Rothe H, Becker H, Beissbarth T, Homayounfar K, Gauss K, Kitz J, Wolff H, Scheel AH, Ghadimi M, Rödel C, Conradi LC, Liersch T.

Am J Surg Pathol. 2013 Aug;37(8):1283-9. doi: 10.1097/PAS.0b013e3182886ced.

PMID:
23851331
28.

Gender affects acute organ toxicity during radiochemotherapy for rectal cancer: long-term results of the German CAO/ARO/AIO-94 phase III trial.

Wolff HA, Conradi LC, Beissbarth T, Leha A, Hohenberger W, Merkel S, Fietkau R, Raab HR, Tschmelitsch J, Hess CF, Becker H, Wittekind C, Sauer R, Rödel C, Liersch T; German Rectal Cancer Study Group.

Radiother Oncol. 2013 Jul;108(1):48-54. doi: 10.1016/j.radonc.2013.05.009. Epub 2013 Jun 11.

29.

Metastatic recurrence after complete resection of colorectal liver metastases: impact of surgery and chemotherapy on survival.

Homayounfar K, Bleckmann A, Conradi LC, Sprenger T, Lorf T, Niessner M, Sahlmann CO, Meller J, Liersch T, Ghadimi BM.

Int J Colorectal Dis. 2013 Jul;28(7):1009-17. doi: 10.1007/s00384-013-1648-2. Epub 2013 Feb 1.

30.

Frequency of HER-2 positivity in rectal cancer and prognosis.

Conradi LC, Styczen H, Sprenger T, Wolff HA, Rödel C, Nietert M, Homayounfar K, Gaedcke J, Kitz J, Talaulicar R, Becker H, Ghadimi M, Middel P, Beissbarth T, Rüschoff J, Liersch T.

Am J Surg Pathol. 2013 Apr;37(4):522-31. doi: 10.1097/PAS.0b013e318272ff4d.

PMID:
23282976
31.

Enrichment of CD133-expressing cells in rectal cancers treated with preoperative radiochemotherapy is an independent marker for metastasis and survival.

Sprenger T, Conradi LC, Beissbarth T, Ermert H, Homayounfar K, Middel P, Rüschoff J, Wolff HA, Schüler P, Ghadimi BM, Rödel C, Becker H, Rödel F, Liersch T.

Cancer. 2013 Jan 1;119(1):26-35. doi: 10.1002/cncr.27703. Epub 2012 Jun 26.

32.

Survivin as a prognostic/predictive marker and molecular target in cancer therapy.

Rödel F, Sprenger T, Kaina B, Liersch T, Rödel C, Fulda S, Hehlgans S.

Curr Med Chem. 2012;19(22):3679-88. Review.

PMID:
22680927
33.

[Total mesorectal excision with and without preoperative radiotherapy for patients with resectable rectal cancer: The multicentre, randomised controlled TME trial 12-year follow-up].

Wolff HA, Liersch T.

Strahlenther Onkol. 2012 Jul;188(7):634-5. doi: 10.1007/s00066-012-0132-1. German. No abstract available.

PMID:
22659943
34.

Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial.

Rödel C, Liersch T, Becker H, Fietkau R, Hohenberger W, Hothorn T, Graeven U, Arnold D, Lang-Welzenbach M, Raab HR, Sülberg H, Wittekind C, Potapov S, Staib L, Hess C, Weigang-Köhler K, Grabenbauer GG, Hoffmanns H, Lindemann F, Schlenska-Lange A, Folprecht G, Sauer R; German Rectal Cancer Study Group.

Lancet Oncol. 2012 Jul;13(7):679-87. doi: 10.1016/S1470-2045(12)70187-0. Epub 2012 May 23.

PMID:
22627104
35.

Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.

Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C, Becker H, Raab HR, Villanueva MT, Witzigmann H, Wittekind C, Beissbarth T, Rödel C.

J Clin Oncol. 2012 Jun 1;30(16):1926-33. doi: 10.1200/JCO.2011.40.1836. Epub 2012 Apr 23.

PMID:
22529255
36.

Rectal cancer: state of the art in 2012.

Rödel C, Hofheinz R, Liersch T.

Curr Opin Oncol. 2012 Jul;24(4):441-7. doi: 10.1097/CCO.0b013e328352ea02. Review.

PMID:
22450150
37.

Bilobar spreading of colorectal liver metastases does not significantly affect survival after R0 resection in the era of interdisciplinary multimodal treatment.

Homayounfar K, Bleckmann A, Conradi LC, Sprenger T, Beissbarth T, Lorf T, Niessner M, Sahlmann CO, Meller J, Becker H, Liersch T, Ghadimi BM.

Int J Colorectal Dis. 2012 Oct;27(10):1359-67. Epub 2012 Mar 21.

38.

Optimal lymph node harvest in rectal cancer (UICC stages II and III) after preoperative 5-FU-based radiochemotherapy. Acetone compression is a new and highly efficient method.

Gehoff A, Basten O, Sprenger T, Conradi LC, Bismarck C, Bandorski D, Merkelbach-Bruse S, Schneider-Stock R, Stoehr R, Wirtz RM, Kitz J, Müller A, Hartmann A, Becker H, Ghadimi BM, Liersch T, Rüschoff J.

Am J Surg Pathol. 2012 Feb;36(2):202-13. doi: 10.1097/PAS.0b013e31823fa35b.

PMID:
22251939
39.

[(68)Ga-labeled peptides for clinical trials - production according to the German Drug Act: the Göttingen experience].

Meller B, Angerstein C, Liersch T, Ghadimi M, Sahlmann CO, Meller J.

Nuklearmedizin. 2012;51(2):55-64. doi: 10.3413/nukmed-0435-11-10. Epub 2012 Feb 17. German.

PMID:
22249368
40.

[Rectal cancer: current status of multimodal therapy--when and how?].

Gaedcke J, Liersch T, Hess C, Becker H, Rödel C, Ghadimi BM.

Zentralbl Chir. 2011 Aug;136(4):334-42. doi: 10.1055/s-0031-1271581. Epub 2011 Aug 23. Review. German.

PMID:
21863511
41.

[Gastrointestinal tumors--interdisciplinary discussion over new data].

Arnold D, Fietkau R, Hegewisch-Becker S, Höhler T, Knoefel WT, Kubicka S, Lang H, Liersch T, Luster M, Oettle H, Reinacher-Schick A, Ridwelski K, Riess H, Rödel C, Rüschoff J, Schmiegel W, Schmoll HJ, Vanhoefer U.

Onkologie. 2011;34 Suppl 3:1-31. doi: 10.1159/000328047. Epub 2011 Apr 27. German. No abstract available.

42.

Gender-specific acute organ toxicity during intensified preoperative radiochemotherapy for rectal cancer.

Wolff HA, Conradi LC, Schirmer M, Beissbarth T, Sprenger T, Rave-Fränk M, Hennies S, Hess CF, Becker H, Christiansen H, Liersch T.

Oncologist. 2011;16(5):621-31. doi: 10.1634/theoncologist.2010-0414. Epub 2011 May 9.

43.

Comparison of chromosomal aberrations in primary colorectal carcinomas to their pulmonary metastases.

Danner BC, Gerdes JS, Jung K, Sander B, Enders C, Liersch T, Seipelt R, Gutenberg A, Gunawan B, Schöndube FA, Füzesi L.

Cancer Genet. 2011 Mar;204(3):122-8. doi: 10.1016/j.cancergen.2010.12.003.

PMID:
21504711
44.

Thymidylate synthase as a prognostic biomarker for locally advanced rectal cancer after multimodal treatment.

Conradi LC, Bleckmann A, Schirmer M, Sprenger T, Jo P, Homayounfar K, Wolff HA, Rothe H, Middel P, Becker H, Ghadimi MB, Beissbarth T, Liersch T.

Ann Surg Oncol. 2011 Sep;18(9):2442-52. doi: 10.1245/s10434-011-1608-4. Epub 2011 Feb 23.

45.

Novel Carcinoembryonic-Antigen-(CEA)-Specific Pretargeting System to Assess Tumor Cell Viability after Irradiation of Colorectal Cancer Cells.

Meller B, Rave-Fränck M, Breunig C, Schirmer M, Baehre M, Nadrowitz R, Liersch T, Meller J.

Strahlenther Onkol. 2011 Feb;187(2):120-6. doi: 10.1007/s00066-010-2191-5. Epub 2011 Jan 24.

PMID:
21271227
46.

Targeting NCA-95 and other granulocyte antigens and receptors with radiolabeled monoclonal antibodies (Mabs).

Meller J, Liersch T, Oezerden MM, Sahlmann CO, Meller B.

Q J Nucl Med Mol Imaging. 2010 Dec;54(6):582-98. Review.

PMID:
21221067
47.

Induction chemotherapy before chemoradiotherapy and surgery for locally advanced rectal cancer : is it time for a randomized phase III trial?

Rödel C, Arnold D, Becker H, Fietkau R, Ghadimi M, Graeven U, Hess C, Hofheinz R, Hohenberger W, Post S, Raab R, Sauer R, Wenz F, Liersch T.

Strahlenther Onkol. 2010 Dec;186(12):658-64. doi: 10.1007/s00066-010-2194-2. Epub 2010 Nov 30. Review.

PMID:
21136027
48.

Failure of downregulation of survivin following neoadjuvant radiochemotherapy in rectal cancer is associated with distant metastases and shortened survival.

Sprenger T, Rödel F, Beissbarth T, Conradi LC, Rothe H, Homayounfar K, Wolff HA, Ghadimi BM, Yildirim M, Becker H, Rödel C, Liersch T.

Clin Cancer Res. 2011 Mar 15;17(6):1623-31. doi: 10.1158/1078-0432.CCR-10-2592. Epub 2010 Nov 30.

49.

The role of survivin for radiation oncology: moving beyond apoptosis inhibition.

Rödel F, Reichert S, Sprenger T, Gaipl US, Mirsch J, Liersch T, Fulda S, Rödel C.

Curr Med Chem. 2011;18(2):191-9. Review.

PMID:
21110807
50.

Stage II/III rectal cancer with intermediate response to preoperative radiochemotherapy: do we have indications for individual risk stratification?

Sprenger T, Rothe H, Jung K, Christiansen H, Conradi LC, Ghadimi BM, Becker H, Liersch T.

World J Surg Oncol. 2010 Apr 13;8:27. doi: 10.1186/1477-7819-8-27.

Supplemental Content

Loading ...
Support Center